There has been an increasing interest in positron emission tomography (PET) agents targeting prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on PCa cells, for imaging and directing therapy of PCa [2]. Here, FOLH1 is linked to posterior cortical atrophy.